报价延迟最少15分钟:2026/10/01 10:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
369.71 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
8.21/9.17
|
|
企业价值
11.45B
|
| 资产负债 |
|
每股账面净值
268.30
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
2.58B
|
|
每股收益
101.74
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
